Could immunosignatures technology enable the development of a preventative cancer vaccine?

Luhui Shen, Debra Hansen, Stephen Johnston, Joseph B arten Legutki

Research output: Contribution to journalArticle

Abstract

The exciting prospect of developing a universal prophylactic cancer vaccine now seems more possible due to advances in technology and basic knowledge. However, the problem of testing the efficacy of such a vaccine in a clinical trial seems daunting. The low incidence and long lead-time to diagnosis of cancer would make a standard clinical trial long and expensive. Recently, we demonstrated that the immunosignatures diagnostic technology could be useful in evaluating vaccines. The technology is based on profiling the antibody diversity in an individual on a peptide chip platform. Here we propose that this technology may also enable a clinical trial of a preventative vaccine. Preliminary evidence supports the prospect of immunosignatures detecting cancer at very early stages, well before conventional diagnosis. Because the technology is simple and inexpensive, it could be used to monitor the occurrence of cancer in participants and shorten the clinical trial.

Original languageEnglish (US)
Pages (from-to)577-579
Number of pages3
JournalExpert Review of Vaccines
Volume13
Issue number5
DOIs
StatePublished - May 1 2014

    Fingerprint

ASJC Scopus subject areas

  • Medicine(all)

Cite this